Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Top Cited Papers
- 11 February 2010
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 362 (6) , 504-512
- https://doi.org/10.1056/nejmoa0903627
Abstract
Some 50% of patients with visceral leishmaniasis (kala-azar) worldwide live in the Indian state of Bihar. Liposomal amphotericin B is an effective treatment when administered in short courses. We wanted to determine whether the efficacy of a single infusion of liposomal amphotericin B was inferior to conventional parenteral therapy, consisting of 15 alternate-day infusions of amphotericin B deoxycholate.Keywords
This publication has 18 references indexed in Scilit:
- Cost‐effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, IndiaTropical Medicine & International Health, 2009
- ABLE: A New and Improved Amphotericin B for Visceral Leishmaniasis?The American Journal of Tropical Medicine and Hygiene, 2009
- New Treatment Approach in Indian Visceral Leishmaniasis: Single‐Dose Liposomal Amphotericin B Followed by Short‐Course Oral MiltefosineClinical Infectious Diseases, 2008
- Amphotericin B Treatment for Indian Visceral Leishmaniasis: Response to 15 Daily versus Alternate-Day InfusionsClinical Infectious Diseases, 2007
- Injectable Paromomycin for Visceral Leishmaniasis in IndiaNew England Journal of Medicine, 2007
- Advances in leishmaniasisPublished by Elsevier ,2005
- Amphotericin B Treatment for Indian Visceral Leishmaniasis: Conventional versus Lipid FormulationsClinical Infectious Diseases, 2004
- Single‐Dose Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis in India: A Multicenter StudyClinical Infectious Diseases, 2003
- Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.The American Journal of Tropical Medicine and Hygiene, 2002
- Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial Commentary: cost and resistance remain issuesBMJ, 2001